When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
A bill to lower the price of insulin drugs and supplies for more North Dakotans attracted passionate discussion at a Thursday ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
A $2.48 million grant from the Lilly Endowment is expected to help Baylor University expand its Black Gospel Archive and ...